Sunday, October 19, 2025
Your Health 247
Advertisement
  • Home
  • Health
  • Fitness
  • Diseases
  • Nutrition
  • Weight Loss
  • Meditation
  • Wellbeing Tips
  • Suppliments
  • Yoga
No Result
View All Result
  • Home
  • Health
  • Fitness
  • Diseases
  • Nutrition
  • Weight Loss
  • Meditation
  • Wellbeing Tips
  • Suppliments
  • Yoga
No Result
View All Result
Your Health 247
No Result
View All Result
Home Health

Oral drug combination extends progression-free survival in advanced ER-positive breast cancer

Your Health 247 by Your Health 247
October 18, 2025
in Health
0 0
0
Oral drug combination extends progression-free survival in advanced ER-positive breast cancer
0
SHARES
7
VIEWS
Share on FacebookShare on Twitter


Three-dimensional culture of human breast cancer cells, with DNA stained blue and a protein in the cell surface membrane stained green. Credit: NCI Center for Cancer Research, National Cancer Institute, National Institutes of Health

Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation selective estrogen receptor degrader and full antagonist, compared to a standard combination approach. These findings, from the phase 3 evERA Breast Cancer study, are presented today by Dr. Erica Mayer of Dana-Farber Cancer Institute at the annual meeting of the European Society for Medical Oncology (ESMO) in Berlin, Germany.

Tumors that express the estrogen receptor (ER) account for roughly 70% of all breast cancer cases and metastatic forms of these ER-positive cancers can be difficult to treat. In addition, the development of resistance to current endocrine therapies poses a major challenge for both clinicians and patients, underscoring the need for novel therapies that effectively target this breast cancer subtype.

“There is a significant need for therapies for metastatic ER-positive breast cancers that are more effective, particularly for patients whose tumors develop resistance to current endocrine therapies and who have progressed following treatment with CDK 4/6 inhibitors,” says Dr. Mayer. “In addition, we also need tolerable therapies that partner well with existing targeted agents and overall will improve outcomes for patients in the second line setting and beyond—when resistance is common and can be challenging to overcome.”

Giredestrant is a next-generation selective estrogen receptor degrader and full antagonist or SERD. It works by binding to the estrogen receptor and promoting its degradation, thus preventing estrogen from stimulating cancer growth. This new SERD has two important features compared to existing drugs. First, it has a unique mechanism of action relative to other hormone-blocking agents, which means it could benefit patients who develop resistance to current therapies. Second, giredestrant is administered orally, which is more convenient for patients than the monthly injections required for first-generation drugs.

evERA is a global phase 3, randomized, open-label study evaluating the use of giredestrant, in combination with everolimus, an mTOR targeting drug, in patients with ER-positive, HER-2-negative advanced breast cancer. This all-oral regimen is compared to a standard of care combination of endocrine therapy plus everolimus. evERA is the first positive, head-to-head phase 3 study of an all-oral SERD-containing regimen versus a standard of care combination.

A total of 373 patients were enrolled and randomized to receive either giredestrant plus everolimus or standard of care endocrine therapy and everolimus. About 55% of patients had mutations in the estrogen receptor gene (ESR1), indicating potential resistance to endocrine therapy. The study was designed to look for improvement in progression-free survival (PFS) using the giredestrant-based regimen in all patients (intention to treat, ITT) and in the subset of patients whose tumor had the ESR1 mutations.

With a median follow-up of 18.6 months, patients with tumors harboring an ESR1 mutation who received the giredestrant-containing regimen showed a statistically significant improvement in median PFS of 9.99 months, compared to 5.45 months for those who received the standard of care combination. That corresponds to a 63% reduction in the risk of disease progression or death.

In the ITT population, which includes patients with ESR1 mutations and those without, the patients who received the giredestrant combination showed a statistically significant improvement in median PFS of 8.77 months compared to 5.49 months for those treated with the standard of care combination. That corresponds to a 44% reduction in the risk of disease progression or death.

The overall survival data from the study remain immature but are trending favorably. In addition, the safety profile of the giredestrant regimen was manageable and consistent with the known safety profiles of the individual study treatments.

“Although we’ve made great progress in treating metastatic ER-positive, HER-2-negative breast cancer, these cancers can become resistant to existing therapies making them difficult to treat,” says Dr. Mayer. “The combination of giredestrant and everolimus is designed to address the most common resistance mechanisms. The evERA study is the first trial in this setting to show that using this new combination can substantially improve disease control compared to a standard of care combination regimen and may provide great benefit to a large number of patients with advanced breast cancer.”

Provided by
Dana-Farber Cancer Institute

Citation:
Oral drug combination extends progression-free survival in advanced ER-positive breast cancer (2025, October 18)
retrieved 18 October 2025
from https://medicalxpress.com/news/2025-10-oral-drug-combination-free-survival.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



Source link

Tags: AdvancedBreastcancercombinationdrugERpositiveextendsOralprogressionfreesurvival
Previous Post

Nanoparticles offer new hope for treating alcohol-related liver disease

Next Post

This One Supplement Puts Me To Sleep Fast — Without Side Effects*

Next Post
This One Supplement Puts Me To Sleep Fast — Without Side Effects*

This One Supplement Puts Me To Sleep Fast — Without Side Effects*

Facebook Twitter Instagram Youtube RSS
Your Health 247

Discover the latest in health and fitness with Your Health 247. Get expert advice, workout routines, healthy recipes, and mental wellness tips to lead a healthier, happier life. Stay informed and empowered with us!

CATEGORIES

  • Diseases
  • Fitness
  • Health
  • Meditation
  • Nutrition
  • Suppliments
  • Weight Loss
  • Wellbeing Tips
  • Yoga
No Result
View All Result

SITEMAP

  • About Us
  • Advertise with Us
  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Health
  • Fitness
  • Diseases
  • Nutrition
  • Weight Loss
  • Meditation
  • Wellbeing Tips
  • Suppliments
  • Yoga

Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In